ghk-cu chemical structure image structures of GHK and its copper and palmitoylated (Pal) Copper Tripeptide-1 (GHK-Cu) (CAS: 49557-75-7)

To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet

If you spot copper tripeptide-1 on an ingredient list, youve found the thing your feed keeps hyping

S., Drobintseva, A

Many trials employ highly selective eligibility criteria that exclude older adults, patients with multimorbidity, and individuals with complex medical or social needs